I85PREP
⌘ K
Iraqi Board Clinical Pharmacy study materials
Iraqi Board Clinical Pharmacy study resources

Iraqi Board Clinical Pharmacy practice questions

One question at a time. Build your Iraqi Board Clinical Pharmacy understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Clinical Pharmacokinetics and Pharmacodynamics

A 70 kg patient receives a loading dose of vancomycin 25 mg/kg intravenously. Assuming a volume of distribution of 0.7 L/kg, what is the approximate peak serum concentration immediately after the dose is fully distributed?

  1. About 36 mg/L Correct answer.
  2. About 18 mg/L
  3. About 51 mg/L
  4. About 25 mg/L

Explanation

Loading dose equals Vd multiplied by the target concentration, so concentration equals dose divided by Vd. The dose is 1750 mg and the Vd is 49 L, giving roughly 36 mg/L. This relationship assumes the drug has distributed and that no elimination has yet occurred.

Question 2Clinical Pharmacokinetics and Pharmacodynamics

Which pharmacokinetic parameter best predicts the average steady-state plasma concentration of a drug given by continuous intravenous infusion?

  1. Clearance Correct answer.
  2. Volume of distribution
  3. Bioavailability
  4. Half-life

Explanation

At steady state during continuous infusion, concentration equals infusion rate divided by total clearance. Clearance therefore determines the plateau level independent of distribution. Volume of distribution and half-life govern how quickly that plateau is approached, not its magnitude.

Question 3Clinical Pharmacokinetics and Pharmacodynamics

A drug is eliminated by first-order kinetics. If the plasma half-life is 6 hours, approximately what fraction of the steady-state concentration is reached after 24 hours of a constant-rate infusion started without a loading dose?

  1. About 75%
  2. About 50%
  3. About 94% Correct answer.
  4. About 99%

Explanation

After four half-lives, accumulation reaches roughly 1 minus 0.5 to the fourth power, which is about 94% of steady state. Each half-life halves the remaining gap to plateau. This is the basis for the common practice of waiting about four to five half-lives before assessing steady state.

Question 4Clinical Pharmacokinetics and Pharmacodynamics

Which statement correctly describes the relationship between bioavailability and the extent of systemic absorption after extravascular administration?

  1. Bioavailability expresses the fraction of the dose reaching systemic circulation unchanged Correct answer.
  2. Bioavailability expresses the fraction of drug bound to plasma albumin
  3. Bioavailability expresses the volume into which the drug distributes
  4. Bioavailability expresses the speed at which the peak concentration is attained

Explanation

Bioavailability is defined as the fraction of an administered dose that reaches the systemic circulation in unchanged form, comparing the extravascular area under the curve with the intravenous reference. Rate of absorption is described separately by parameters such as Tmax and Ka. Protein binding and distribution volume are distinct pharmacokinetic properties.

Question 5Clinical Pharmacokinetics and Pharmacodynamics

A patient with a creatinine clearance of 30 mL/min is prescribed a renally eliminated drug whose normal maintenance dose assumes normal renal function. Which adjustment is most appropriate when the desired peak concentration must be preserved?

  1. Administer the usual dose more frequently
  2. Reduce the dose while keeping the same interval
  3. Extend the dosing interval while keeping the same dose Correct answer.
  4. Double the dose and halve the interval

Explanation

When renal clearance falls, total clearance falls and the maintenance requirement per unit time decreases. Extending the interval while keeping the dose preserves the peak concentration, which matters for concentration-dependent killing. Dose reduction at the same interval lowers the peak and is better suited when toxicity is peak-related.

Question 6Clinical Pharmacokinetics and Pharmacodynamics

Two formulations of the same orally administered drug are compared. Formulation A produces a much higher peak concentration but the same total area under the curve as formulation B. What is the most accurate interpretation?

  1. Formulation B is likely to cause more concentration-dependent toxicity
  2. The two formulations are bioequivalent in extent but differ in absorption rate Correct answer.
  3. Formulation A has higher bioavailability than formulation B
  4. The two formulations are bioequivalent in both rate and extent

Explanation

Equal area under the curve indicates equal extent of absorption, so the formulations are equivalent in bioavailability. A higher peak with the same area reflects faster absorption, which is a difference in rate rather than extent. Bioequivalence criteria require similarity in both rate and extent.

Question 7Clinical Pharmacokinetics and Pharmacodynamics

Aminoglycosides are best dosed using which pharmacodynamic rationale?

  1. Concentration-independent killing with no post-antibiotic effect
  2. Time-dependent killing requiring continuous infusion
  3. Concentration-dependent killing with a prolonged post-antibiotic effect Correct answer.
  4. Killing that depends mainly on the area under the curve relative to the trough

Explanation

Aminoglycoside killing is concentration-dependent, so a high peak relative to the minimum inhibitory concentration drives efficacy. They also exhibit a prolonged post-antibiotic effect, which supports extended-interval dosing. This combination allows high peaks with a low trough to limit nephrotoxicity and ototoxicity.

Question 8Clinical Pharmacokinetics and Pharmacodynamics

Vancomycin therapy is best monitored using which pharmacodynamic index?

  1. Area under the curve relative to the minimum inhibitory concentration Correct answer.
  2. Time above the minimum inhibitory concentration
  3. Trough concentration relative to the half-life
  4. Peak concentration relative to the minimum inhibitory concentration

Explanation

Vancomycin efficacy is best predicted by the ratio of the 24-hour area under the curve to the minimum inhibitory concentration. Guidelines favour AUC-guided dosing over trough-only monitoring because it improves efficacy while limiting nephrotoxicity. Peak-to-MIC ratio is the index for aminoglycosides, and time above MIC applies to beta-lactams.

Question 9Clinical Pharmacokinetics and Pharmacodynamics

A drug has a narrow therapeutic index and is highly bound to albumin. In a patient with severe hypoalbuminaemia, which change is expected for a highly extracted drug given intravenously?

  1. Unbound concentration will fall in proportion to the fall in albumin
  2. Total plasma concentration may fall while unbound concentration is largely preserved Correct answer.
  3. Total concentration will rise because less drug is bound
  4. Unbound concentration will rise markedly because clearance falls

Explanation

For a highly extracted drug, clearance depends mainly on liver blood flow and is relatively insensitive to protein binding. As albumin falls, total concentration declines because less drug is bound, but the unbound fraction and unbound concentration are largely maintained. Monitoring total concentrations alone can therefore mislead in hypoalbuminaemia.

Question 10Clinical Pharmacokinetics and Pharmacodynamics

A patient taking phenytoin for epilepsy develops hypoalbuminaemia. The measured total phenytoin concentration is 6 mg/L. Which interpretation is most appropriate?

  1. The unbound concentration may be within range despite a low total value Correct answer.
  2. The low total concentration indicates accelerated metabolism
  3. The total concentration confirms subtherapeutic free drug
  4. The dose should be increased to raise the total concentration above 10 mg/L

Explanation

Phenytoin is highly albumin-bound, so hypoalbuminaemia lowers total concentration without necessarily lowering free drug. Free phenytoin should be measured or the total corrected for albumin before changing the dose. Reacting to the total value alone risks unnecessary dose escalation and toxicity.

Question 11Clinical Pharmacokinetics and Pharmacodynamics

A drug follows Michaelis-Menten (saturable) kinetics. What happens to the steady-state concentration if the daily dose is doubled while liver enzymes remain saturated?

  1. It falls because clearance increases
  2. It doubles exactly
  3. It remains unchanged
  4. It rises by more than double the original concentration Correct answer.

Explanation

With saturated enzymes, elimination rate approaches a constant maximum and cannot rise with concentration. Doubling the dose therefore produces a disproportionate, greater-than-proportional rise in steady-state concentration. This nonlinearity is why phenytoin doses are titrated in small increments.

Question 12Clinical Pharmacokinetics and Pharmacodynamics

Which statement about the apparent volume of distribution is correct?

  1. It describes the rate of drug elimination from plasma
  2. It equals the plasma volume in all patients
  3. It is always smaller than total body water
  4. It relates the amount of drug in the body to the plasma concentration Correct answer.

Explanation

Volume of distribution is a proportionality constant linking the amount of drug in the body to its plasma concentration. It is an apparent value and can greatly exceed total body water when drugs concentrate in tissues. It conveys no information about the rate of elimination.

Question 13Clinical Pharmacokinetics and Pharmacodynamics

A patient receives a continuous infusion of a drug with a half-life of 12 hours. Approximately how long until steady state is reached?

  1. About 48 to 60 hours Correct answer.
  2. About 12 hours
  3. About 24 hours
  4. About 120 hours

Explanation

Steady state is generally reached after about four to five half-lives, which here is 48 to 60 hours. Each half-life closes half of the remaining gap to plateau. This rule applies to drugs following linear kinetics.

Question 14Clinical Pharmacokinetics and Pharmacodynamics

Which factor most directly determines the maintenance dose rate of a drug in a patient with stable hepatic and renal function?

  1. The elimination half-life alone
  2. The fraction bound to plasma proteins alone
  3. Volume of distribution alone
  4. Total clearance and the target steady-state concentration Correct answer.

Explanation

Maintenance dose rate equals clearance multiplied by the target steady-state concentration. Clearance captures the patient's actual eliminating capacity across organs. Volume of distribution and half-life influence the loading dose and time to plateau rather than the maintenance requirement.

Question 15Clinical Pharmacokinetics and Pharmacodynamics

A patient with cirrhosis has reduced hepatic clearance of a low-extraction drug. What is the most likely consequence for oral bioavailability?

  1. It decreases because absorption is impaired
  2. It remains unchanged because extraction is low
  3. It increases because first-pass metabolism is reduced Correct answer.
  4. It increases because plasma protein binding falls

Explanation

Low-extraction drugs are incompletely removed on first pass, and their bioavailability depends on the fraction escaping hepatic metabolism. When intrinsic clearance falls in cirrhosis, less drug is metabolised on first pass and bioavailability rises. This can lead to unexpectedly high systemic exposure after oral dosing.

Question 16Clinical Pharmacokinetics and Pharmacodynamics

Which of the following best explains why a loading dose is used before starting a maintenance infusion?

  1. To increase the elimination half-life of the drug
  2. To compensate for reduced clearance in renal impairment
  3. To reach therapeutic concentrations rapidly without waiting several half-lives Correct answer.
  4. To prevent accumulation during chronic therapy

Explanation

Without a loading dose, a constant infusion requires about four to five half-lives to reach steady state. A loading dose fills the volume of distribution quickly so that therapeutic concentrations are achieved sooner. It does not alter clearance, half-life, or the final steady-state level.

Question 17Clinical Pharmacokinetics and Pharmacodynamics

A drug is a high-extraction substrate of hepatic metabolism. Which change will most affect its oral bioavailability?

  1. A change in plasma protein binding
  2. A change in renal filtration
  3. A change in hepatic blood flow Correct answer.
  4. A change in the volume of distribution

Explanation

For high-extraction drugs, first-pass metabolism is limited by hepatic blood flow, and bioavailability approximates one minus the extraction ratio. Changes in liver blood flow therefore alter the fraction surviving first pass. Protein binding and distribution volume have much less influence on this flow-limited process.

Question 18Clinical Pharmacokinetics and Pharmacodynamics

Aminoglycoside monitoring after an extended-interval dose typically involves measuring which concentrations?

  1. A single random concentration
  2. Two troughs on consecutive days
  3. A peak shortly after infusion and a trough before the next dose Correct answer.
  4. Only the peak concentration

Explanation

Extended-interval aminoglycoside dosing uses a high peak to drive concentration-dependent killing and a low trough to limit toxicity. Both are measured: the peak to confirm adequate exposure and the trough to ensure clearance before the next dose. Trough-guided adjustment protects against accumulation in renal impairment.

Question 19Clinical Pharmacokinetics and Pharmacodynamics

Which statement best describes the post-antibiotic effect?

  1. The time required for a drug to reach peak concentration
  2. Persistent suppression of bacterial growth after antibiotic concentrations fall below the MIC Correct answer.
  3. Increased bacterial killing while concentrations exceed the MIC
  4. The reduction in clearance caused by infection

Explanation

The post-antibiotic effect is the continued suppression of bacterial regrowth after exposure to an antibiotic has ended and concentrations fall below the MIC. It is prominent with aminoglycosides and supports extended-interval dosing. It is distinct from the killing that occurs while concentrations exceed the MIC.

Question 20Clinical Pharmacokinetics and Pharmacodynamics

A patient on a constant infusion of a drug with linear kinetics has a steady-state concentration of 20 mg/L at 100 mg/hour. If the infusion rate is increased to 150 mg/hour, what steady-state concentration is expected?

  1. 40 mg/L
  2. 15 mg/L
  3. 30 mg/L Correct answer.
  4. 20 mg/L

Explanation

Under linear kinetics, steady-state concentration is proportional to infusion rate because clearance is constant. Increasing the rate by 50% raises the concentration by 50%, from 20 to 30 mg/L. This proportionality fails only when elimination becomes saturable.

Question 21Clinical Pharmacokinetics and Pharmacodynamics

Which pharmacodynamic concept explains why beta-lactam efficacy is best optimised by prolonged or continuous infusion?

  1. Killing that depends on the trough concentration relative to the MIC
  2. A prolonged post-antibiotic effect against gram-negative bacilli
  3. Time-dependent killing with the fraction of the dosing interval above the MIC Correct answer.
  4. Concentration-dependent killing with a high peak-to-MIC ratio

Explanation

Beta-lactams exhibit time-dependent killing, so efficacy correlates with the percentage of the dosing interval during which free drug exceeds the MIC. Prolonged or continuous infusion maximises this fraction. Aminoglycosides, by contrast, are concentration-dependent with a prolonged post-antibiotic effect.

Question 22Clinical Pharmacokinetics and Pharmacodynamics

A drug is 90% bound to plasma albumin. What does this imply about the unbound fraction?

  1. It is 0.90 and determines the volume of distribution
  2. It is 0.10 and is the pharmacologically active fraction Correct answer.
  3. It is 0.90 and is the pharmacologically active fraction
  4. It is 0.10 and represents drug stored in tissues

Explanation

The unbound fraction equals one minus the bound fraction, so a drug that is 90% bound has an unbound fraction of 0.10. Only unbound drug can cross membranes and interact with receptors, so it drives pharmacological effect. Bound drug acts as a circulating reservoir.

Question 23Clinical Pharmacokinetics and Pharmacodynamics

A patient has a creatinine clearance of 20 mL/min and is to receive a drug that is 90% renally eliminated. Which principle guides the maintenance dose adjustment?

  1. Increase the maintenance dose to overcome reduced absorption
  2. Reduce the loading dose to match the lower clearance
  3. Keep the dose unchanged because hepatic metabolism compensates
  4. Reduce the maintenance dose in proportion to the fall in clearance Correct answer.

Explanation

Maintenance dosing depends on total clearance, so a drug eliminated mainly by the kidney requires reduction when renal clearance falls. The adjustment is roughly proportional to the reduction in clearance. Loading dose depends on volume of distribution, which is usually unchanged in renal impairment.

Question 24Clinical Pharmacokinetics and Pharmacodynamics

Which statement about the elimination half-life of a drug is correct?

  1. It equals the time to reach steady state
  2. It depends only on the dose administered
  3. It is independent of volume of distribution
  4. It is determined by both clearance and volume of distribution Correct answer.

Explanation

Half-life is proportional to volume of distribution divided by clearance, so changes in either parameter alter it. It is not a fixed property of the drug and can change with organ function or distribution. Steady state is reached in about four to five half-lives, not one.

Question 25Pharmacotherapy of Cardiovascular and Renal Disease

A 62-year-old man with heart failure and reduced ejection fraction (HFrEF, EF 30%) is stable on enalapril and carvedilol. Which add-on therapy has the strongest evidence for reducing cardiovascular death and heart failure hospitalization in this setting?

  1. Dapagliflozin Correct answer.
  2. Furosemide
  3. Digoxin
  4. Amlodipine

Explanation

SGLT2 inhibitors such as dapagliflozin reduce cardiovascular death and heart failure hospitalization in HFrEF regardless of diabetes status and are now part of guideline-directed medical therapy. Loop diuretics relieve congestion but do not improve mortality. Amlodipine and digoxin do not carry this mortality benefit.

Question 26Pharmacotherapy of Cardiovascular and Renal Disease

Which laboratory parameter should be monitored most closely after starting an ACE inhibitor in a patient with bilateral renal artery stenosis?

  1. Hemoglobin A1c
  2. Prothrombin time
  3. Serum amylase
  4. Serum potassium and creatinine Correct answer.

Explanation

ACE inhibitors reduce glomerular filtration pressure in the stenotic kidney and can precipitate acute kidney injury and hyperkalemia, so serum creatinine and potassium require close monitoring. The other parameters are unrelated to ACE inhibitor renal and potassium effects.

Question 27Pharmacotherapy of Cardiovascular and Renal Disease

A patient on warfarin for atrial fibrillation has an INR of 6.5 with no bleeding. Which is the most appropriate immediate management?

  1. Continue warfarin at the same dose
  2. Start a direct oral anticoagulant today
  3. Hold warfarin and give oral vitamin K Correct answer.
  4. Give fresh frozen plasma immediately

Explanation

For an INR above 4.5 to 10 without bleeding, guidelines recommend withholding warfarin and administering low-dose oral vitamin K. Fresh frozen plasma is reserved for serious bleeding. Continuing the same dose risks further elevation, and switching anticoagulants acutely is not appropriate.

Question 28Pharmacotherapy of Cardiovascular and Renal Disease

Which class of antihypertensive is preferred as initial therapy in a Black patient without diabetes or chronic kidney disease?

  1. Alpha-1 blocker monotherapy
  2. Beta blocker monotherapy
  3. Thiazide diuretic or calcium channel blocker Correct answer.
  4. ACE inhibitor monotherapy

Explanation

In Black patients without CKD or diabetes, thiazide diuretics and calcium channel blockers produce better blood pressure response than ACE inhibitor monotherapy. ACE inhibitors are less effective as monotherapy in this group, and beta blockers and alpha blockers are not preferred initial agents.

Question 29Pharmacotherapy of Cardiovascular and Renal Disease

A patient with acute decompensated heart failure is started on intravenous furosemide. Which electrolyte abnormality is most likely to develop?

  1. Hypokalemia Correct answer.
  2. Hyperkalemia
  3. Hypercalcemia
  4. Hypernatremia

Explanation

Loop diuretics increase distal sodium delivery and potassium excretion, causing hypokalemia and hypomagnesemia. They do not typically cause hyperkalemia, hypernatremia, or hypercalcemia; in fact they increase calcium excretion.

Question 30Pharmacotherapy of Cardiovascular and Renal Disease

Which monitoring is essential when initiating spironolactone in a patient with HFrEF already on an ACE inhibitor?

  1. Liver enzymes
  2. Serum potassium and creatinine Correct answer.
  3. Serum lipase
  4. Thyroid function tests

Explanation

Spironolactone is a potassium-sparing diuretic, and combined with an ACE inhibitor it substantially increases the risk of hyperkalemia and renal impairment. Potassium and creatinine must be checked at baseline and shortly after initiation. Lipase, thyroid function, and liver enzymes are not the key safety parameters.

Question 31Pharmacotherapy of Cardiovascular and Renal Disease

A patient with chronic kidney disease and type 2 diabetes has an eGFR of 25 mL/min/1.73 m2. Which glucose-lowering agent requires dose reduction or avoidance at this level of kidney function?

  1. Insulin glargine
  2. Metformin Correct answer.
  3. Sitagliptin
  4. Empagliflozin

Explanation

Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m2 because of the risk of lactic acidosis. Empagliflozin can be initiated down to eGFR 20, insulin requires individualized titration rather than avoidance, and sitagliptin requires dose reduction but is not contraindicated.

Question 32Pharmacotherapy of Cardiovascular and Renal Disease

Which finding suggests digoxin toxicity in a patient with atrial fibrillation taking digoxin?

  1. Yellow-green visual halos with nausea Correct answer.
  2. Dry cough with angioedema
  3. Polyuria with hypernatremia
  4. Bradycardia with hypertension

Explanation

Digoxin toxicity classically causes visual disturbances such as yellow-green halos, gastrointestinal symptoms, and arrhythmias. Dry cough and angioedema suggest ACE inhibitor effects, while the other options are not characteristic of digoxin toxicity.

Question 33Pharmacotherapy of Cardiovascular and Renal Disease

A patient with heart failure and fluid overload is prescribed both furosemide and an NSAID for osteoarthritis. What is the most important concern?

  1. NSAIDs prevent hypokalemia
  2. NSAIDs increase furosemide absorption excessively
  3. NSAIDs blunt diuretic efficacy and worsen fluid retention Correct answer.
  4. NSAIDs enhance the natriuretic effect

Explanation

NSAIDs inhibit prostaglandin-mediated renal vasodilation and sodium excretion, reducing diuretic response and promoting fluid retention and renal impairment in heart failure. They do not enhance diuresis, prevent hypokalemia, or cause excessive furosemide absorption.

Question 34Pharmacotherapy of Cardiovascular and Renal Disease

Which agent is most appropriate for rate control in a patient with atrial fibrillation and HFrEF?

  1. Verapamil
  2. Flecainide
  3. Metoprolol succinate Correct answer.
  4. Diltiazem

Explanation

Beta blockers such as metoprolol succinate are preferred for rate control in HFrEF because they also improve outcomes. Non-dihydropyridine calcium channel blockers like verapamil and diltiazem are negative inotropes and should be avoided in HFrEF, and flecainide is contraindicated in structural heart disease.

Question 35Pharmacotherapy of Cardiovascular and Renal Disease

A patient with an acute ST-elevation myocardial infarction is given aspirin. Which additional antiplatelet agent is standard in the dual antiplatelet regimen after primary PCI?

  1. Warfarin
  2. Rivaroxaban
  3. Ticagrelor Correct answer.
  4. Apixaban

Explanation

Dual antiplatelet therapy after primary PCI combines aspirin with a P2Y12 inhibitor such as ticagrelor, prasugrel, or clopidogrel. Warfarin, apixaban, and rivaroxaban are anticoagulants, not antiplatelet agents, and are not part of routine DAPT.

Question 36Pharmacotherapy of Cardiovascular and Renal Disease

Which adverse effect is most characteristic of amiodarone and requires long-term monitoring?

  1. Angioedema and cough
  2. Hypoglycemia and weight gain
  3. Hyperkalemia and renal failure
  4. Thyroid dysfunction and pulmonary toxicity Correct answer.

Explanation

Amiodarone accumulates in tissues and causes thyroid dysfunction, pulmonary fibrosis, hepatic injury, and corneal deposits, requiring periodic monitoring. Hyperkalemia, angioedema, and hypoglycemia are not characteristic amiodarone effects.

Question 37Pharmacotherapy of Cardiovascular and Renal Disease

A patient with hypertension and gout requires a thiazide-like diuretic. Which consideration is most relevant?

  1. Thiazides have no effect on uric acid
  2. Thiazides raise serum uric acid and may precipitate gout flares Correct answer.
  3. Thiazides reduce uric acid excretion only in CKD
  4. Thiazides lower uric acid and protect against gout

Explanation

Thiazide and thiazide-like diuretics reduce renal uric acid excretion and can raise serum urate, precipitating gout flares. They do not lower uric acid or protect against gout.

Question 38Pharmacotherapy of Cardiovascular and Renal Disease

Which statin-related adverse effect requires immediate discontinuation and creatine kinase assessment?

  1. Dry skin
  2. Constipation
  3. Muscle pain with weakness and elevated CK Correct answer.
  4. Mild transient headache

Explanation

Statin-associated muscle symptoms with weakness and elevated creatine kinase raise concern for myopathy or rhabdomyolysis, warranting discontinuation and CK measurement. Headache, constipation, and dry skin are not indicators of statin myotoxicity.

Question 39Pharmacotherapy of Cardiovascular and Renal Disease

A patient with heart failure and reduced ejection fraction is on optimal medical therapy but remains symptomatic. Which combination is most appropriate to add for further mortality benefit?

  1. Sacubitril/valsartan in place of an ACE inhibitor Correct answer.
  2. Adding an ACE inhibitor to sacubitril/valsartan
  3. Adding an ARB to an ACE inhibitor
  4. Adding ivabradine plus an ACE inhibitor

Explanation

Sacubitril/valsartan provides greater mortality benefit than enalapril in HFrEF and should replace, not be combined with, an ACE inhibitor because of angioedema risk. Combining ACE inhibitor and ARB increases adverse effects without benefit, and ivabradine is used for symptom and hospitalization reduction in selected patients, not as a mortality combination.

Question 40Pharmacotherapy of Cardiovascular and Renal Disease

A patient with resistant hypertension on three agents including a diuretic has a high aldosterone-to-renin ratio. Which agent is most appropriate to add?

  1. Furosemide
  2. Hydralazine
  3. Clonidine
  4. Spironolactone Correct answer.

Explanation

Primary aldosteronism is a common cause of resistant hypertension, and mineralocorticoid receptor antagonists such as spironolactone are the preferred add-on. Loop diuretics, central alpha-2 agonists, and direct vasodilators are not targeted therapy for aldosterone excess.

Question 41Pharmacotherapy of Cardiovascular and Renal Disease

A patient with chronic kidney disease and hyperkalemia is given sodium polystyrene sulfonate. Which adverse effect is most concerning?

  1. Hypercalcemia
  2. Intestinal necrosis, especially with sorbitol Correct answer.
  3. Thyroid storm
  4. Hypernatremia requiring fluid restriction

Explanation

Sodium polystyrene sulfonate has been associated with gastrointestinal necrosis, particularly when formulated with sorbitol and in patients with ileus or postoperative states. It does not cause hypercalcemia or thyroid storm, and hypernatremia is not the principal concern.

Question 42Pharmacotherapy of Cardiovascular and Renal Disease

Which parameter should guide the dose of enoxaparin in a patient with severe renal impairment (CrCl < 30 mL/min)?

  1. Serum magnesium
  2. INR
  3. Platelet count only
  4. Anti-Xa activity and renal function Correct answer.

Explanation

Enoxaparin is renally cleared, and in severe renal impairment the dose should be reduced or anti-Xa monitoring considered. INR reflects warfarin, platelet count monitors heparin-induced thrombocytopenia but not dose, and magnesium is unrelated.

Question 43Pharmacotherapy of Cardiovascular and Renal Disease

A patient with HFrEF and a history of angioedema on an ACE inhibitor requires renin-angiotensin blockade. Which is the safest choice?

  1. Sacubitril/valsartan Correct answer.
  2. Enalapril
  3. Ramipril
  4. Lisinopril

Explanation

In patients with ACE inhibitor-related angioedema, an ARB or sacubitril/valsartan may be considered with caution, though sacubitril/valsartan carries its own angioedema warning. Rechallenge with any ACE inhibitor is contraindicated.

Question 44Pharmacotherapy of Cardiovascular and Renal Disease

Which mechanism explains the antihypertensive effect of amlodipine?

  1. Inhibition of sodium-glucose cotransporter 2
  2. Inhibition of angiotensin-converting enzyme
  3. Blockade of beta-1 adrenergic receptors
  4. Blockade of L-type calcium channels in vascular smooth muscle Correct answer.

Explanation

Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. ACE inhibition, beta-1 blockade, and SGLT2 inhibition describe other drug classes.

Question 45Pharmacotherapy of Cardiovascular and Renal Disease

A patient on furosemide develops hypokalemia. Which combination is most likely to worsen potassium loss?

  1. Concurrent spironolactone
  2. Concurrent hydrocortisone therapy Correct answer.
  3. Concurrent ACE inhibitor
  4. Concurrent potassium supplement

Explanation

Corticosteroids promote renal potassium excretion and can exacerbate diuretic-induced hypokalemia. Spironolactone, ACE inhibitors, and potassium supplements all raise or preserve potassium rather than worsen loss.

Question 46Pharmacotherapy of Cardiovascular and Renal Disease

Which statement about aspirin in secondary prevention of cardiovascular disease is correct?

  1. Aspirin should be combined with an NSAID routinely
  2. Aspirin replaces anticoagulation in atrial fibrillation
  3. Aspirin is recommended for primary prevention in all adults over 40
  4. Low-dose aspirin reduces recurrent events in patients with established atherosclerotic disease Correct answer.

Explanation

Aspirin provides clear net benefit in secondary prevention after myocardial infarction or stroke. Routine primary prevention is not recommended for all adults because bleeding risk may outweigh benefit, and aspirin does not replace anticoagulation in atrial fibrillation.

Question 47Pharmacotherapy of Cardiovascular and Renal Disease

A patient with heart failure and reduced ejection fraction has a heart rate of 80 bpm on maximally tolerated beta blocker. Which agent is most appropriate to add for further symptom benefit?

  1. Digoxin
  2. Diltiazem
  3. Ivabradine Correct answer.
  4. Atenolol

Explanation

Ivabradine reduces heart rate by inhibiting the funny current in the sinoatrial node and is used in symptomatic HFrEF with sinus rhythm and heart rate at or above 70 bpm despite beta blocker. Atenolol and diltiazem are not preferred in HFrEF, and digoxin is not the first choice for rate reduction in this setting.

Question 48Pharmacotherapy of Cardiovascular and Renal Disease

A patient with CKD and anemia is prescribed an erythropoiesis-stimulating agent. Which monitoring is most important?

  1. Hemoglobin and blood pressure Correct answer.
  2. Serum amylase
  3. Prothrombin time
  4. Serum calcium only

Explanation

Erythropoiesis-stimulating agents can cause hypertension and excessive hemoglobin rise with thrombotic risk, so hemoglobin and blood pressure require monitoring. Amylase, prothrombin time, and calcium alone are not the key parameters.

Question 49Pharmacotherapy of Infectious Diseases and Antimicrobial Stewardship

A patient with a documented anaphylactic allergy to penicillin requires treatment for a serious infection. Which antimicrobial class should be avoided because of the highest risk of cross-reactivity?

  1. Aminoglycosides
  2. Fluoroquinolones
  3. Macrolides
  4. Carbapenems Correct answer.

Explanation

Carbapenems share the beta-lactam ring structure with penicillins and carry the highest cross-reactivity risk among the listed classes, though the true rate is lower than historically taught. Macrolides, aminoglycosides, and fluoroquinolones have unrelated structures and are not cross-reactive with penicillin.

Question 50Pharmacotherapy of Infectious Diseases and Antimicrobial Stewardship

Which laboratory parameter is the most reliable marker of systemic inflammation used to guide duration of antibiotic therapy in a hospitalized patient with sepsis?

  1. Serum potassium
  2. Serum creatinine
  3. Hemoglobin concentration
  4. Procalcitonin trend Correct answer.

Explanation

Procalcitonin rises rapidly in bacterial infection and falls with effective therapy and clinical resolution, and its trend can support decisions to shorten antibiotic courses. Creatinine, hemoglobin, and potassium reflect organ function or electrolytes rather than the inflammatory response to infection.